


AZD5462 (AstraZeneca)


oral RXFP1 agonist



- Relaxin mimic for treating cardiorenal disease
- Significant improvement in cardiac ejection fraction in cyno monkeys with HFrEF
- Planned Ph. I trial to assess safety and PK

GS-248 (Boehringer)


mPGES1 inhibitor



- Preclinical for the treatment of pain & inflammation
- Picomolar hWBA potency (0.4 nM)
- From a partnership with Gesynta Pharma

M1069 (Merck)


A_{2a}/A_{2b} inhibitor



- Ph. I for treating advanced solid malignancies
- Enhances the in vivo efficacy of paclitaxel and cisplatin in a 4T1 tumor model
- High selectivity against A₁ and A₃ receptors

RPT193 (RAPT)


oral CCR4 antagonist



- Ph. IIb for the treatment of atopic dermatitis
- Blocks the recruitment of Th2 cells
- >200x selective for CCR4 vs. other chemokine receptors

RG7774 (Roche)


oral CB₂R agonist



- Ph. II for treatment-naïve diabetic retinopathy
- Multiparameter optimization after an HTS campaign
- High selectivity for CB₂ over CB₁ receptor

Compound 30 (GSK)


inhaled PI4KB inhibitor



- Ph. I for the treatment of COPD
- Designed using structure-kinetic relationships
- Long residence time (~40h) minimizes toxic tissue accumulation

BI-456906 (Boehringer)

GCGR/GLP-1R agonist



- Derived from endogenous hormones GCG and GLP-1
- Increases energy expenditure and decreases intake
- Currently in Ph. II development for obesity and NASH